Table 2.
Patient characteristics in PC subgroup analyses
| Characteristics | Low PC group
|
P | High PC group
|
P | ||
|---|---|---|---|---|---|---|
| B+C (%) (n=26) | C (%) (n=116) | B+C (%) (n=33) | C (%) (n=109) | |||
| Sex | 0.36 | 0.01 | ||||
| Male | 20 (76.9) | 76 (65.5) | 15 (45.5) | 76 (69.7) | ||
| Female | 6 (23.1) | 40 (34.5) | 18 (54.5) | 33 (30.3) | ||
| Age (median, range) years | 54 (32–75) | 57 (23–87) | 0.12 | 49 (24–75) | 55 (19–80) | 0.19 |
| ≤60 | 20 (76.9) | 69 (59.5) | 27 (81.8) | 75 (68.8) | ||
| >60 | 6 (23.1) | 47 (40.5) | 6 (18.2) | 34 (31.2) | ||
| Primary tumor location | 0.66 | 0.91 | ||||
| Right colon | 6 (23) | 37 (31.9) | 11 (33.3) | 33 (30.2) | ||
| Left colon | 10 (38.5) | 43 (37.1) | 10 (30.3) | 32 (29.4) | ||
| Rectum | 10 (38.5) | 36 (31.0) | 12 (36.4) | 44 (40.4) | ||
| Pathological type | 0.07 | 0.32 | ||||
| Well differentiated | 1 (3.8) | 2 (1.7) | 0 (0) | 0 (0) | ||
| Moderately differentiated | 19 (73.0) | 74 (63.8) | 22 (66.7) | 62 (56.9) | ||
| Poorly differentiated | 1 (3.8) | 28 (24.1) | 9 (27.3) | 26 (23.9) | ||
| Mucinous adenocarcinoma | 5 (19.2) | 9 (7.8) | 2 (6.0) | 19 (17.4) | ||
| Unknowna | 0 (0) | 3 (2.6) | 0 (0) | 2 (1.8) | ||
| Pathologic tumor classification | 0.71 | 0.61 | ||||
| T1 | 1 (3.8) | 1 (0.9) | 1 (3.0) | 1 (0.9) | ||
| T2 | 0 (0) | 2 (1.7) | 2 (6.1) | 5 (4.6) | ||
| T3 | 9 (34.6) | 15 (12.9) | 8 (24.2) | 18 (16.5) | ||
| T4 | 16 (61.5) | 98 (84.5) | 22 (66.7) | 83 (76.2) | ||
| Unknownb | 0 (0) | 0 (0) | 0 (0) | 2 (1.8) | ||
| Lymphatic invasion | 16 (61.5) | 85 (73.3) | 0.34 | 24 (72.7) | 76 (69.7) | 0.83 |
| Vascular invasion | 2 (7.7) | 8 (6.9) | 0.89 | 9 (27.3) | 7 (6.4) | 0.003 |
| Perineural invasion | 1 (3.8) | 1 (0.9) | 0.33 | 4 (12.1) | 2 (1.8) | 0.03 |
| First-line chemotherapy regimen | 0.18 | 0.06 | ||||
| Oxaliplatin-based | 17 (65.4) | 93 (80.2) | 18 (54.5) | 85 (78.0) | ||
| Irinotecan-based | 8 (30.8) | 15 (12.9) | 12 (36.4) | 18 (16.4) | ||
| Fluorouracil alone | 0 (0) | 1 (0.9) | 1 (3.0) | 3 (2.8) | ||
| Oxaliplatin plus irinotecan | 1 (3.8) | 7 (6.0) | 2 (6.1) | 3 (2.8) | ||
Notes:
a
These patients were pathologically diagnosed with colorectal adenocarcinoma without the differentiation degree using the biopsy specimen or pathology consultation of specimen from other hospitals.;
b
These patients had no primary tumor specimen.
Abbreviations: PC, perivascular cell coverage; B+C, bevacizumab plus chemotherapy group; C, chemotherapy group.